SVCM
DYN icon

Saturn V Capital Management’s Dyne Therapeutics DYN Stock Holding History

Saturn V Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.5M Buy
1,057,493
+90,884
+9% +$1.69M 3.37% 13
2026
Q1 		$17.5M Sell
966,609
-822,007
-46% -$14.2M 3.17% 13
2025
Q4 		$35M Sell
1,788,616
-885,853
-33% -$16.8M 6.42% 6
2025
Q3 		$33.8M Buy
2,674,469
+1,219,040
+84% +$13.9M 7.42% 4
2025
Q2 		$13.9M Buy
+1,455,429
New +$16M 5.62% 9

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Saturn V Capital Management's DYN Position: Q2 2026 in Review

Saturn V Capital Management increased its Dyne Therapeutics (DYN) stake by 9.4% in Q2 2026, buying an estimated $1.69M and bringing the position to 1,057,493 shares worth $23.5M. The position accounts for 3.37% of the portfolio, ranked #13.

Saturn V Capital Management first reported a position in DYN in Q2 2025 and has held it in 5 quarters since. The position peaked at $35M in Q4 2025. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Saturn V Capital Management held 1,057,493 shares of Dyne Therapeutics worth $23.5M as of Q2 2026.
  • Saturn V Capital Management bought 90,884 Dyne Therapeutics shares in Q2 2026, an estimated $1.69M.
  • Dyne Therapeutics made up 3.37% of Saturn V Capital Management's portfolio in Q2 2026, its #13 holding.
  • Saturn V Capital Management first reported a position in Dyne Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Saturn V Capital Management's Dyne Therapeutics position peaked at $35M in Q4 2025.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Saturn V Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.